Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today

被引：2
|
作者：
Bloomgarden, Zachary T. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2019年 / 157卷
关键词：
DIPEPTIDYL-PEPTIDASE-IV; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; METAANALYSIS; SITAGLIPTIN; RISK;
D O I：
10.1016/j.diabres.2019.107906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [41] MEDI 415-Cyclopropylglycine amide derivatives as potent DPP-IV inhibitors for the treatment of diabetes
    Thomas, Abraham
    Kadam, Ashok
    Pawar, Mangesh
    Shah, Daisy
    Varanasi, Kanthikiran
    Raghuram, Anupindi
    Narayanan, Shridhar
    Vakkalanka, Swaroop V.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [42] In Silico ADMET Evaluation of Natural DPP-IV Inhibitors for Rational Drug Design against Diabetes
    Singla, Rajeev K.
    Shen, Bairong
    CURRENT DRUG METABOLISM, 2020, 21 (10) : 768 - 777
  • [43] Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
    Chong, Shiau Chin
    Sukor, Norlela
    Robert, Sarah Anne
    Ng, Kim Fong
    Kamaruddin, Nor Azmi
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [44] The minimal blood glucose variability is observed in type 2 diabetic patients on metformin plus DPP-IV inhibitors
    Smirnov, I. I.
    Zhuravlyova, L. V.
    Ilchenko, I. A.
    DIABETOLOGIA, 2011, 54 : S340 - S340
  • [45] Design, Synthesis, Biological Screening, and Molecular Docking Studies of Piperazine-Derived Constrained Inhibitors of DPP-IV for the Treatment of Type 2 Diabetes
    Kushwaha, Ram N.
    Srivastava, Rohit
    Mishra, Akansha
    Rawat, Arun K.
    Srivastava, Arvind K.
    Haq, Wahajul
    Katti, Seturam B.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (04) : 439 - 446
  • [46] The DPP-IV inhibitor Linagliptin reported to be effective and safe in patients with type 2 diabetes independent of renal function
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2011, 13 (09): : 867 - 867
  • [47] DPP-IV inhibitors (2): Synthesis and evaluation of novel 2-cyano-4-fluoropyrrolidines.
    Fukushima, H
    Hiratate, A
    Takahashi, M
    Kitano, K
    Yamamoto, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U16 - U17
  • [48] CADABA FARINOSA CONTAIN COMPOUNDS OF NATURAL ORIGIN WITH POTENT DIPEPTIDYL PEPTIDASE-IV (DPP-IV) INHIBITORS USED TO TREAT TYPE II DIABETES
    Ismail, S. Ibrahim
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A126 - A126
  • [49] Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials
    Gao, W.
    Dong, J.
    Liu, J.
    Li, Y.
    Liu, F.
    Yang, L.
    Zhou, X.
    Liao, L.
    DIABETES OBESITY & METABOLISM, 2014, 16 (02): : 179 - 185
  • [50] To investigate the efficacy of dipeptidyl peptidase-IV (DPP-IV) inhibitor therapy in multiethnic Asian patients with type 2 diabetes mellitus
    Andres, Julia
    Yeo, Jia Xuan
    Khoo, Chin Meng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S123 - S124
12345